Millions of Americans rely daily on this type of heart-helping medication. See if this newly provided alert impacts your ...

Teva Pharmaceutical Industries Limited (NYSE:TEVA) Goldman Sachs 46th Annual Global Healthcare Conference June 10, 2025 8:00 AM ETCompany ...

Teva Pharmaceutical Industries announces plans to transform into a leading biopharmaceutical company, targeting $5 billion in innovative medicines by 2030.

Teva’s innovative portfolio continues to drive strong performance and future potential. The company has announced its target to build a >$5 billion innovative medicines franchise by 2030, driven by ...

Teva Pharmaceuticals, a US affiliate of Teva Pharmaceutical Industries Ltd., and Sanofi presented new, detailed results from the RELIEVE UCCD phase 2b study of duvakitug (TEV’574/SAR447189), a human ...

Teva and Sanofi's duvakitug showed promising results in a Phase 2b study for ulcerative colitis and Crohn's disease, with plans for a Phase 3 trial in 2025.

Sanofi and Teva Pharmaceuticals, a US affiliate of Teva Pharmaceutical Industries Ltd., today presented new, detailed results from the RELIEVE UCCD phase 2b study of duvakitug, a human IgG1-λ2 ...

New detailed data from the RELIEVE UCCD study support overall efficacy and safety of duvakitug in all pre-specified subgroups across the different dosesNew endpoints presented include findings on ...

Teva hosting investor call Monday, February 24 at 8:00 a.m. U.S. ET New detailed data from the RELIEVE UCCD study support overall efficacy and safety of duvakitug in all pre-specified subgroups ...